Q3 2024 Earnings Forecast for Viking Therapeutics, Inc. Issued By William Blair (NASDAQ:VKTX)

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities researchers at William Blair cut their Q3 2024 earnings per share (EPS) estimates for Viking Therapeutics in a report released on Wednesday, July 24th. William Blair analyst A. Hsieh now forecasts that the biotechnology company will post earnings of ($0.23) per share for the quarter, down from their prior forecast of ($0.20). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.01) per share. William Blair also issued estimates for Viking Therapeutics’ Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.11) EPS.

Several other equities research analysts have also recently issued reports on VKTX. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Viking Therapeutics in a research note on Thursday, July 25th. Raymond James boosted their price target on Viking Therapeutics from $116.00 to $118.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 25th. Truist Financial reiterated a “buy” rating and issued a $120.00 price target on shares of Viking Therapeutics in a research note on Monday, June 17th. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a research note on Thursday, June 27th. Finally, Maxim Group reiterated a “buy” rating and issued a $120.00 price target on shares of Viking Therapeutics in a research note on Tuesday, June 4th. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $111.78.

Viking Therapeutics Stock Down 7.7 %

Shares of NASDAQ:VKTX opened at $56.52 on Monday. Viking Therapeutics has a 12-month low of $8.28 and a 12-month high of $99.41. The stock has a market cap of $6.26 billion, a PE ratio of -60.77 and a beta of 1.03. The business has a 50 day moving average of $55.45 and a 200-day moving average of $57.23.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. During the same period in the prior year, the firm posted ($0.19) EPS.

Insider Transactions at Viking Therapeutics

In other news, CFO Greg Zante sold 66,756 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the completion of the transaction, the chief financial officer now directly owns 174,854 shares in the company, valued at $13,059,845.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Greg Zante sold 66,756 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the completion of the transaction, the chief financial officer now directly owns 174,854 shares in the company, valued at $13,059,845.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Zante Greg 16,136 shares of the firm’s stock in a transaction on Tuesday, July 30th. The disclosure for this trade can be found here. Company insiders own 4.70% of the company’s stock.

Institutional Trading of Viking Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VKTX. Massmutual Trust Co. FSB ADV acquired a new stake in Viking Therapeutics in the first quarter valued at $25,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Viking Therapeutics in the second quarter valued at $27,000. Lindbrook Capital LLC increased its holdings in Viking Therapeutics by 370.7% in the first quarter. Lindbrook Capital LLC now owns 353 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 278 shares during the period. Wetzel Investment Advisors Inc. acquired a new stake in Viking Therapeutics in the fourth quarter valued at $37,000. Finally, LifeSteps Financial Inc. acquired a new stake in Viking Therapeutics in the first quarter valued at $37,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.